Pfizer ,Clear Creek Bio to Collaborate on Targeting SARS-CoV-2 Papain-Like Protease

 

• Agreement aims to advance discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral antivirals in the fight against COVID-19

• Expands Pfizer’s innovative anti-infective pipeline, complementing the company’s existing portfolio of COVID-19 products

https://finance.yahoo.com/news/pfizer-clear-creek-bio-collaborate-114500791.html